Roseanne sells GLPG 46.55: This suggests that Galapagos might proceed with the development of filgotinib on its own, even if the drug maker fails to find a new development partner.

After the termination of the partnership, Galapagos is now getting ready to test the candidate in phase II trial on its own. The partnership included development of GLPG1690 for the treatment of idiopathic pulmonary fibrosis (IPF), a dangerous lung-scarring condition. Earlier in 2015, Galapagos has announced the termination of its collaboration pact with J&J, which the companies entered into in 2007. The companies had agreed to join hands for the development of treatments for inflammatory diseases. These experimental programs have made Galapagos an interesting takeover target for drug makers such as Johnson & Johnson ( NYSE:JNJ ) and AbbVie which are planning to expand into the said treatment markets. Galapagos is also testing the same candidate, filgotinib, and another experimental drug as a potential treatment for irritable bowel disorders.


Arlena:
Galapagos announced that the other 2 year old partnership between the drug makers on cystic fibrosis is still intact.

Georgetta:
Galapagos had entered into two development partnerships with AbbVie, one on rheumatoid arthritis and one on cystic fibrosis.

Felicitas:
This seems to increase the chances of Galapagos finding another partner to further develop its arthritis drug.

Sarah:
Filgotinib, similar to ABT-494, is a JAK-1 inhibitor, a new class of drugs.

Janeen:
ABT-494, is an internally developed investigational selective JAK1 inhibitor.

Ping:
Upon the results, the drug maker announced that it would be graduating the experimental drug to its late stage clinical trials.

Therese:
The trials tested the drug in patients who were not responding adequately to two commonly prescribed arthritis treatments, TNF inhibitors and methotrexate.

Berry:
The trials were conducted on patients who failed to respond adequately to two of the usually prescribed drugs for arthritis treatment, methotrexate and TNF inhibitors.

Adah:
AbbVie, on the other hand, fell by 1.5% during the trading.

Charmaine:
Deerfield Management also holds a large position in Galapagos, holding 642,608 shares valued at $33.09 million, according to its recent 13F filing.

Galapagos Nv Sp ADR (NASDAQ:GLPG)
//stockhand.net/us/?q=nasdaq%3Aglpg&id=632776